NASDAQ:MGNX

MacroGenics - MGNX Stock Forecast, Price & News

$3.43

-0.28 (-7.55%)

(As of 10/5/2022 10:50 AM ET)

Add

Compare

Today's Range: $3.42
▼
$3.68
50-Day Range: $3.01
▼
$5.22
52-Week Range: $2.13
▼
$22.68

Volume: 3,966 shs
Average Volume: 555,800 shs
Market Capitalization: $210.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.33

MacroGenics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.63 Rating Score
Upside/Downside: 232.4% Upside
$12.33 Price Target
Short Interest: Bearish
8.15% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.61
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.24) to ($2.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

217th out of 1,087 stocks

Pharmaceutical Preparations Industry

93rd out of 546 stocks

4.3

Analyst's Opinion

Consensus Rating
MacroGenics has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.33, MacroGenics has a forecasted upside of 232.4% from its current price of $3.71.
Amount of Analyst Coverage
MacroGenics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
8.15% of the float of MacroGenics has been sold short.
Short Interest Ratio / Days to Cover
MacroGenics has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in MacroGenics has recently decreased by 0.81%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
MacroGenics does not currently pay a dividend.
Dividend Growth
MacroGenics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
MacroGenics has received a 66.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Monoclonal antibodies" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for MacroGenics is -1.61.

2.7

News and Social Media Coverage

News Sentiment
MacroGenics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for MacroGenics this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for MGNX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
MarketBeat Follows
4 people have added MacroGenics to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MacroGenics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.90% of the stock of MacroGenics is held by insiders.

1.3

Earnings and Valuation

Earnings Growth
Earnings for MacroGenics are expected to grow in the coming year, from ($2.24) to ($2.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MacroGenics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MacroGenics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MacroGenics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MacroGenics (NASDAQ:MGNX) Stock

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Stock News Headlines

October 1, 2022 | reuters.com

MGNX.OQ - MacroGenics Inc | Stock Price & Latest News | Reuters

September 13, 2022 | finance.yahoo.com

Nacuity Pharmaceuticals and Arctic Therapeutics Enter Licensing Agreement and Strategic Partnership to Develop NPI-001 - Yahoo Finance

September 12, 2022 | fool.com

Why MacroGenics Stock Sank Today - The Motley Fool

September 6, 2022 | streetinsider.com

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer - StreetInsider.com

September 6, 2022 | businesswire.com

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer - Business Wire

September 2, 2022 | seekingalpha.com

Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics - Seeking Alpha

August 29, 2022 | markets.businessinsider.com

Where Macrogenics Stands With Analysts

August 21, 2022 | nasdaq.com

MacroGenics (NASDAQ:MGNX) Will Have To Spend Its Cash Wisely - Nasdaq

August 14, 2022 | finance.yahoo.com

Brokers Are Upgrading Their Views On MacroGenics, Inc. (NASDAQ:MGNX) With These New Forecasts

August 12, 2022 | finance.yahoo.com

Wall Street Analysts Predict a 291% Upside in MacroGenics (MGNX): Here's What You Should Know

August 10, 2022 | finance.yahoo.com

Biopharmaceuticals Market with 7.5% CAGR Between 2022 to 2030, Top key players, Size, Share, Recent Developments, Opportunities, Challenges, Growth Plus Reports - Yahoo Finance

August 9, 2022 | finance.yahoo.com

MacroGenics Jumps Biotech Layoff Bandwagon, Cuts 15% Of Workforce

August 9, 2022 | benzinga.com

Macrogenics: Q2 Earnings Insights - Benzinga

August 9, 2022 | finance.yahoo.com

MacroGenics (MGNX) Q2 2022 Earnings Call Transcript

August 8, 2022 | greenwichtime.com

MacroGenics: Q2 Earnings Snapshot - Greenwich Time

August 8, 2022 | globenewswire.com

MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results - GlobeNewswire

August 5, 2022 | seekingalpha.com

MacroGenics Q2 2022 Earnings Preview (NASDAQ:MGNX) - Seeking Alpha

August 4, 2022 | nasdaq.com

National Vision (EYE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Nasdaq

July 25, 2022 | globenewswire.com

MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call - GlobeNewswire

July 25, 2022 | finance.yahoo.com

MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call

July 20, 2022 | rttnews.com

Pre-market Movers: ELBM, SDIG, GP, RVMD, MGNX… - RTTNews

July 18, 2022 | seekingalpha.com

MacroGenics stock slips after SMBC Nikko downgrades to neutral - Seeking Alpha

July 14, 2022 | markets.businessinsider.com

Analyst Ratings for Macrogenics

July 12, 2022 | finance.yahoo.com

Analysts Cuts Price Target On MacroGenics - Read Why - Yahoo Finance

July 12, 2022 | finance.yahoo.com

Analysts Cuts Price Target On MacroGenics - Read Why

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Company Calendar

Last Earnings: 8/08/2022
Today: 10/05/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MGNX
CUSIP: N/A
CIK: 1125345
Web: www.macrogenics.com
Phone: (301) 251-5172
Fax: 301-251-5321
Employees: 427
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.33
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +259.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.63
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-202,120,000.00
Net Margins: -326.76%
Pretax Margin: -326.76%
Return on Equity: -102.68%
Return on Assets: -71.87%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.29
Quick Ratio: 3.24

Sales & Book Value

Annual Sales: $77.45 million
Price / Sales: 2.72
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.91 per share
Price / Book: 0.88

Miscellaneous

Outstanding Shares: 61,460,000
Free Float: 56,604,000
Market Cap: $210.81 million
Optionable: Optionable
Beta: 1.92

Key Executives

Dr. Scott Koenig M.D. (Age 70)
Ph.D., Pres, CEO & Director
Comp: $954.14k

Mr. James Karrels (Age 55)
Sr. VP, CFO & Corp. Sec.
Comp: $577.9k

Mr. Eric Blasius Risser (Age 49)
Chief Operating Officer
Comp: $571.98k

Dr. Ezio Bonvini (Age 68)
Sr. VP of Research & Chief Scientific Officer
Comp: $612.21k

Dr. Thomas M. Spitznagel Ph.D. (Age 55)
Sr. VP of Technical Operations
Comp: $550.97k

Dr. Christopher Shayne James M.D.
VP of Investor Relations & Corp. Communications

Mr. Jeffrey Stuart Peters (Age 50)
Sr. VP & Gen. Counsel

Dr. Stephen L. Eck M.D. (Age 67)
Ph.D., Sr. VP of Clinical Devel. & Chief Medical Officer

Ms. Lynn Cilinski (Age 64)
VP, Controller & Treasurer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MGNX Stock - Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGNX shares.
View MGNX analyst ratings or view top-rated stocks.
What is MacroGenics' stock price forecast for 2022?: 8 analysts have issued 1-year price targets for MacroGenics' stock. Their MGNX share price forecasts range from $4.00 to $30.00. On average, they predict the company's stock price to reach $12.33 in the next twelve months. This suggests a possible upside of 232.4% from the stock's current price.
View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts.
How have MGNX shares performed in 2022?: MacroGenics' stock was trading at $16.05 at the beginning of the year. Since then, MGNX shares have decreased by 76.9% and is now trading at $3.71.
View the best growth stocks for 2022 here.
When is MacroGenics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our MGNX earnings forecast.
How were MacroGenics' earnings last quarter?: MacroGenics, Inc. (NASDAQ:MGNX) released its quarterly earnings results on Monday, August, 8th. The biopharmaceutical company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.30. The biopharmaceutical company earned $26.01 million during the quarter, compared to analysts' expectations of $14.59 million. MacroGenics had a negative trailing twelve-month return on equity of 102.68% and a negative net margin of 326.76%.
What is Scott Koenig's approval rating as MacroGenics' CEO?: 12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.

What other stocks do shareholders of MacroGenics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC).
What is MacroGenics' stock symbol?: MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."
How do I buy shares of MacroGenics?: Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is MacroGenics' stock price today?: One share of MGNX stock can currently be purchased for approximately $3.71.
How much money does MacroGenics make?: MacroGenics (NASDAQ:MGNX) has a market capitalization of $228.02 million and generates $77.45 million in revenue each year. The biopharmaceutical company earns $-202,120,000.00 in net income (profit) each year or ($3.56) on an earnings per share basis.
How many employees does MacroGenics have?: The company employs 427 workers across the globe.
How can I contact MacroGenics?: MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The official website for the company is www.macrogenics.com. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at info@macrogenics.com, or via fax at 301-251-5321.

This page (NASDAQ:MGNX) was last updated on 10/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MacroGenics - MGNX Stock Forecast, Price & News

MacroGenics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows